Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

Phase 1 Completed 32 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of temozolomide plus lomustine followed by radiation therapy in treating patients who have high-grade malignant glioma.

Timeline

Start: 2000-11
Primary completion: 2005-01
Completion: 2006-09

Publications

Results Jakacki RI, Yates A, Blaney SM, Zhou T, Timmerman R, Ingle AM, Flom L, Prados MD, Adamson PC, Pollack IF. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008 Aug;10(4):569-76. doi: 10.1215/15228517-2008-019. Epub 2008 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lomustine	Small molecule	90 mg/m2	Oral
Subject	Temozolomide	Small molecule	100 mg/m2	Oral
Subject	Temozolomide	Small molecule	125 mg/m2	Oral
Subject	Temozolomide	Small molecule	160 mg/m2	Oral
Subject	Temozolomide	Small molecule	200 mg/m2	Oral

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications